New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
RBC Capital believes there is an 80%+ chance that Celgene will settle its Revlimid patent case, and the firm thinks that such a deal would enable the shares to "unlock big value." The firm thinks the stock is "very cheap," as it reports that the shares are trading at 7%-9% free cash flow yield. RBC Capital keeps an Outperform rating on the shares.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
08:08 EDTCELGAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
May 18, 2015
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information
May 14, 2015
11:11 EDTCELGAnalysts divided on significance of Celgene blood cancer drug data
Subscribe for More Information
May 13, 2015
17:42 EDTCELGCelgene announces over 55 blood, solid tumor cancer study presentations at ASCO
Subscribe for More Information
May 12, 2015
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use